♦ Learn More About Clinical Trials
A Double-blind Randomized Parallel Group Study of the Efficacy and Safety of Tesevatinib in Subjects with Autosomal Dominant Polycystic Kidney Disease. The primary outcome measures are to change the height adjusted total kidney volume in ADPKD patient in two year time period.
♦ Click here for more information about Tesevatinib in Subjects with ADPKD
A Phase 1b/2a, Safety, Pharmacokinetic and Dose-Escalation Study of KD019 in Subjects with Autosomal Dominant Polycystic Kidney Disease. The primary outcome is to analysis a two year time period of change in glomerular filtration rate (GFR) in ADPKD patients.
♦ Click here for more information about Subjects with ADPKD
A Phase 3b, Multi-center, Open-label Trial to Evaluate the Long -Term Safety of Titrated Immediate-release Tolvaptan (OPC 41061, 30 mg to 120 mg/Day, Split Dose) in Subjects with Autosomal Dominant Polycystic Kidney Disease. The primary outcome is to determine the long-term safety of Tolvaptan in ADPKD patients.
♦ Click here for more information about Tolvaptan in Subjects with ADPKD
A Phase 3, Multi-center, Double-blind, Placebo-controlled, Parallel-arm Trial to Determine Long-term Safety and Efficacy of Oral Tolvaptan Tablets Regimens in Adult Subjects With Autosomal Dominant Polycystic Kidney Disease
♦ Click here for more information about Tolvaptan in Subjects with ADPKD
A Phase 3b, Multi-center, Randomized-withdrawal, Placebo-controlled, Double-blind, Parallel-group Trial to Compare the Efficacy and Safety of Tolvaptan (45 to 120 mg/Day, Split-dose) in Subjects With Chronic Kidney Disease Between Late Stage 2 to Early Stage 4 Due to Autosomal Dominant Polycystic Kidney Disease
♦ Click here for more information about Tolvaptan in Subjects with ADPKD
A Multi-center, Longitudinal, Observational Study of Patients With Autosomal Dominant Polycystic Kidney Disease (ADPKD) to Establish the Rate, Characteristics, and Determinants of Disease Progression
♦ Click here for more information about this study
If you are interested in participating in a PKD Trial, please contact (310) 825-7919 or email PKD@mednet.ucla.edu.
For all general questions and information, please contact (310) 954-2692 or email COREKidney@mednet.ucla.edu.
